Print this Page
E-mail This Page
George R Simon, MD, FACP, FCCP
I have always wanted to be and considered it an honor to be a physician, a privilege that I hold sacrosanct and a responsibility I take very seriously. My ultimate commitment is to my patients whose best interest I hold paramount. By direct patient care, I endeavor to make a difference in current patients' lives and by research and teaching I hope to positively impact the lives of future patients.
I joined the Fox Chase Cancer Center in October of 2008, as Director of Thoracic Oncology in the Separtment of Medical Oncology after having worked in the thoracic division of the H Lee Moffitt Cancer Center in Tampa, Florida. I joined the Fox Chase Cancer Center owing to its very collegial working paradigm, availability of a coterie of outstanding clinicians working in tandem with exceptional basic scientists, all working towards the common goal of enhancing the life expectancies of patients with lung and other cancers and improving the quality of their lives.
Clinically, I specialize in malignancies of the chest, which primarily consist of the various types of lung cancer and mesothelioma. My special interests lie in developing the individualized treatment strategies for patients based on their tumor's molecular profile. Having described the prognostic significance of ERCC1, I was part of team of physicians that investigated the use of ERCC1 as a clinical decision making tool. Additionally, we also showed that chemotherapy for advanced disease or Stage IV could be tailored based on the patients' molecular profile and this could improve response rates and survival. I hope to continue this line investigation at the Fox Chase Cancer Center.
In mesothelioma, we are exploring novel drug combinations both in previously treated and untreated patients.
In the laboratory, we study nuclear excision repair and its effect on the bulky DNA adducts generated by some of the newer platinums. We are also working towards identifying treatment strategies for Stage III Non-Small Cell Lung Cancer, based on markers of nuclear excision repair.
A second area of investigation in the laboratory is glucose metabolism in tumors. Tumors utilize glucose as its primary energy source. We are exploring ways to selectively deprive tumors of glucose in an effort to impede tumor cell growth, enhance tumor cell kill and augment the efficacy of cytotoxic agents.
Medical Oncology
Director of
Thoracic Oncology,
Department of Medical Oncology
Meet the other members of the
lung cancer treatment team.
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497
To make an appointment, call:
215-728-2570.
For general information, call:
1-888-FOX CHASE.
An oncology certified nurse will assist you.
Clinical Expertise:
Medical Education:
MB, BS, Christian Medical College and Hospital, Ludhiana, Punjab India, 1986
Residency:
St. Joseph’s Hospital, Denver CO;
Christian Medical College and Hospital, Ludhiana, Punjab India
Fellowships:
Medical Oncology and Hematology, University of Colorado Health Sciences Center, Denver CO.
Certifications:
American Board of Internal Medicine;
Medical Oncology;
Hematology
Professional Societies:
Invited Member, Thoracic Core Committee of the Eastern Cooperative Oncology Group (ECOG);
Fellow, American College of Physicians (ACP);
Fellow,
American College of Chest Physicians (ACCP);
Member, American Academy of Advancement of Science (AAAS);
Member, American Association for Cancer Research (AACR);
Member,
American Society of Clinical Oncology (SCO);
Member, International Association for the Study of Lung Cancer (IASLC);
Awards:
Research Interests:
Nuclear excision repair; Personalizing chemotherapy for Non-Small Cell Lung Cancer and Glucose metabolism in tumors